Abilify for Bipolar Depression: Limited Evidence and Not FDA-Approved
Abilify (aripiprazole) is NOT FDA-approved for treating bipolar depression and has failed to demonstrate efficacy in controlled trials for this indication. The FDA has only approved aripiprazole for acute mania and maintenance treatment to prevent manic episodes in bipolar I disorder—not for treating depressive episodes 1.
FDA-Approved Indications for Bipolar Disorder
According to the FDA label, Abilify is approved for:
- Acute treatment of manic and mixed episodes associated with Bipolar I Disorder
- Maintenance monotherapy of Bipolar I Disorder (to prevent recurrence of mood episodes)
Notably absent: any indication for acute bipolar depression 1.
What the Evidence Shows
Failed Clinical Trials
Meta-analysis of controlled trials revealed only a weak effect size of 0.17 for acute bipolar depression at 8 weeks—a clinically marginal benefit 2. The evidence suggests aripiprazole's efficacy during maintenance phase is proven only against new manic episodes in patients who had an index manic episode and previously responded to the drug, not for preventing depressive episodes 2.
Why Aripiprazole Failed in Bipolar Depression
The research suggests several reasons for the negative trials 3, 4:
- Doses were too high (typically 10-30 mg), leading to poor tolerability
- Rapid dose titration caused excessive dropout rates
- High placebo response rates in the trials
Alternative Approach: Low-Dose Strategy
Some retrospective data suggests that very low doses (1-5 mg) may be more effective for bipolar II and bipolar NOS depression when used as adjunctive therapy 4. In this study, patients showed improvement with doses of 5 mg or less, with 21% discontinuing due to adverse effects. However, this was uncontrolled, retrospective data in bipolar II/NOS—not the more severe bipolar I disorder.
What IS FDA-Approved for Bipolar Depression
The combination of olanzapine plus fluoxetine is the FDA-approved treatment for bipolar depression in adults 5. This should be your first-line pharmacologic choice when treating acute bipolar depression.
Clinical Bottom Line
Do not use aripiprazole as monotherapy for bipolar depression. If you're considering it at all:
- Only use as adjunctive therapy alongside a proven mood stabilizer (lithium, valproate, or lamotrigine)
- Start with very low doses (2.5-5 mg maximum) if attempting off-label use
- Recognize this is off-label with weak supporting evidence
- Monitor closely for treatment-emergent mania or mood destabilization
- Consider FDA-approved alternatives first: olanzapine-fluoxetine combination, quetiapine, or lurasidone (if available in your formulary)
Common Pitfall to Avoid
Do not assume that because aripiprazole works for mania, it will work for depression—the evidence clearly shows it does not have robust antidepressant effects in bipolar disorder 2. The maintenance data only supports prevention of manic episodes, not depressive episodes 6, 2.